.svg){kind=icon}
Cannabis interacts with a biological system that already exists inside the human body.
That distinction is important.
The body naturally produces signaling molecules known as endocannabinoids, while the cannabis plant produces compounds known as phytocannabinoids. Although the two groups can interact with some of the same receptors and biological pathways, they are not interchangeable.
Understanding the difference can help Florida medical cannabis patients make better sense of THC, CBD, anandamide, CB1 and CB2 receptors, and the broader endocannabinoid system.
It can also help clear up a common misconception: consuming cannabis does not simply replace the cannabinoids your body naturally produces.
What Are Endocannabinoids?
Endocannabinoids are cannabinoid-like signaling molecules created naturally within humans and other animals.
Two of the best studied are:
- Anandamide, also called AEA
- 2-arachidonoylglycerol, commonly called 2-AG
These molecules are part of the endocannabinoid system, or ECS.
The classical ECS includes:
- Endocannabinoids
- CB1 receptors
- CB2 receptors
- Enzymes that produce endocannabinoids
- Enzymes that break them down
Endocannabinoids help regulate communication between cells and participate in processes involving the brain, nervous system, immune system, gastrointestinal system, metabolism, and other tissues.
What Are Phytocannabinoids?
Phytocannabinoids are cannabinoid compounds produced by plants—most notably Cannabis sativa.
The prefix “phyto” simply means plant.
Researchers have identified many phytocannabinoids in cannabis. Some of the best known include:
- THC
- CBD
- CBG
- CBC
- CBN
- THCV
- CBDV
Many phytocannabinoids initially occur in acidic forms within raw cannabis.
For example:
THCA → THC
CBDA → CBD
Heating during smoking, vaporization, cooking, or manufacturing can cause a chemical process known as decarboxylation, converting some cannabinoid acids into their more familiar neutral forms.
The Simplest Difference
A helpful way to remember the distinction is:
Endocannabinoids = made by the body
Phytocannabinoids = made by cannabis
There is also a third category: synthetic cannabinoids, which are created in laboratories.
However, simply belonging to the cannabinoid family does not mean all cannabinoids produce the same effects.
Their receptor activity, metabolism, potency, duration, and pharmacology can differ significantly.
How Endocannabinoids Work
Endocannabinoids usually function as short-lived signaling molecules.
Anandamide and 2-AG may be produced when cells need them rather than continuously circulating at high levels.
After they perform their signaling role, enzymes break them down.
Anandamide is primarily associated with degradation by FAAH, while 2-AG is largely broken down by MAGL.
This rapid production-and-breakdown cycle helps the ECS respond dynamically to changing physiological conditions.
Researchers study endocannabinoid signaling in relation to:
- Pain processing
- Appetite
- Memory
- Stress
- Sleep
- Mood
- Immune activity
- Gastrointestinal function
- Movement
- Metabolism
This does not mean that increasing endocannabinoid activity automatically improves each of these functions. The ECS is a regulatory network, and balance depends on context.
How THC Differs From Anandamide
THC and anandamide can both interact with CB1 receptors, which is one reason cannabis can influence the ECS.
But THC is not simply a plant version of anandamide.
Anandamide is produced naturally when the body needs it and is usually broken down relatively quickly.
THC enters the body from an external source and can activate cannabinoid receptors differently and for a longer period.
THC acts as a partial agonist at CB1 and CB2 receptors, with many of its familiar intoxicating effects associated with CB1 activity in the brain.
These effects may include changes in:
- Perception
- Memory
- Appetite
- Coordination
- Mood
- Pain perception
- Time perception
Dose matters considerably.
Higher THC exposure can increase unwanted effects such as dizziness, anxiety, impaired coordination, sedation, or uncomfortable intoxication.
CBD Works Differently
CBD is also a phytocannabinoid, but it behaves very differently from THC.
CBD has relatively low direct affinity for CB1 and CB2 receptors and influences a wider range of molecular pathways.
Researchers have investigated CBD's interaction with:
- Cannabinoid signaling
- Serotonin receptors
- TRP ion channels
- Drug-metabolizing enzymes
- Anandamide-related pathways
This is why it is misleading to describe CBD simply as “the CB2 cannabinoid.”
Its pharmacology is considerably more complicated.
CBD may also interact with prescription medications, so patients should discuss substantial CBD use with their physician or pharmacist.
What About CBG, CBC, and Other Minor Cannabinoids?
THC and CBD receive most of the attention, but cannabis produces numerous minor phytocannabinoids.
CBG, or cannabigerol, is often described as an important cannabinoid precursor because its acidic form contributes to pathways that eventually produce other cannabinoids.
CBC, or cannabichromene, is another naturally occurring phytocannabinoid being studied for several biological effects.
THCV, CBDV, and other cannabinoids are also under investigation.
Human clinical research involving many minor cannabinoids remains much more limited than research involving THC and CBD.
A laboratory finding involving CBG or CBC should therefore not automatically be interpreted as proof that a dispensary product containing that compound treats a specific medical condition.
CB1 and CB2 Receptors Connect the Two Worlds
The endocannabinoid system provides part of the biological connection between endocannabinoids and phytocannabinoids.
CB1 receptors
CB1 receptors are especially abundant in the brain and central nervous system.
Endocannabinoids such as anandamide can activate CB1 as part of normal physiological signaling.
THC can also activate CB1, producing both potentially useful and unwanted effects.
CB2 receptors
CB2 receptors are strongly associated with immune and peripheral tissues, although they also occur elsewhere.
Endocannabinoids and certain plant-derived compounds can influence CB2-related signaling.
The relationship is not simply one cannabinoid equals one receptor.
Cannabinoids can interact with numerous molecular targets beyond CB1 and CB2.
Do Phytocannabinoids Replace Endocannabinoids?
No.
This is one of the most important concepts for patients to understand.
Using THC does not replace anandamide.
Using CBD does not replace 2-AG.
Instead, phytocannabinoids enter an existing biological signaling network and can modify its activity.
That external influence can be useful in certain medical contexts, but it can also produce unwanted effects depending on the compound, dose, route, patient, and surrounding physiology.
Medical cannabis is therefore better understood as modulating cannabinoid signaling rather than replenishing a missing supply of cannabinoids.
What About Cannabis Terpenes?
Terpenes are another major group of compounds found in cannabis, but they are not cannabinoids.
Common cannabis terpenes include:
- Myrcene
- Limonene
- Pinene
- Linalool
- Humulene
- Beta-caryophyllene
- Terpinolene
Beta-caryophyllene is particularly interesting because it can interact with CB2 receptors.
Even so, a terpene should not be called an endocannabinoid or phytocannabinoid.
Terpenes are chemically distinct compounds.
Research into cannabinoid-terpene interactions continues, but specific terpene combinations cannot yet reliably predict an individual patient's medical outcome.
Why Product Format Still Matters
Even when two products contain THC, administration route can dramatically change the experience.
Inhaled cannabis
Smoking or vaporizing generally produces relatively rapid cannabinoid exposure.
Oral cannabis
Edibles pass through digestion and liver metabolism, generally producing a slower onset and longer duration.
Tinctures
Tinctures may be absorbed partly through tissues in the mouth or swallowed and processed through the gastrointestinal system.
That means “10 mg of THC” cannot always be interpreted identically across routes.
Understanding cannabinoid type is important. Understanding delivery is equally important.
Green Dragon Florida Products as Phytocannabinoid Examples
The following products contain cannabis-derived phytocannabinoids and illustrate different administration formats. They do not contain the body's own endocannabinoids and are not recommendations for treating an endocannabinoid deficiency.
Green Dragon Coco-Nutty #2 Flower — Boynton Beach East
Coco-Nutty #2 Flower is a 3.5-gram whole-flower product currently listed at approximately 23.6% total THC.
Flower demonstrates how a plant-derived cannabinoid such as THC can interact with receptors that normally participate in endogenous cannabinoid signaling.
Circles Tropic Thunder All-in-One — Boynton Beach East
Circles Tropic Thunder All-in-One is a one-gram vaporizer currently listed at approximately 89.8% THC, 0.25% CBD, and 1.08% total terpenes.
Its concentrated cannabinoid profile illustrates why potency and dose should be considered separately. A high percentage does not mean a patient should use more.
Green Dragon Kiwi Strawberry Fast-Acting Chews — Boynton Beach East
Kiwi Strawberry Fast-Acting Chews contain 100 mg of total THC per package.
The oral format highlights another difference between plant-derived THC and endocannabinoids: externally administered cannabinoids must be absorbed and metabolized before producing their effects.
Product availability, cannabinoid percentages, terpene profiles, and laboratory information may change by location and batch.
The Green Dragon Takeaway
Endocannabinoids and phytocannabinoids belong to related areas of cannabinoid science, but they come from very different sources.
Anandamide and 2-AG are produced naturally by the body.
THC, CBD, CBG, CBC, and other phytocannabinoids come from cannabis.
Plant cannabinoids can interact with the body's endocannabinoid signaling network, but they do not simply replace its natural molecules.
For medical cannabis patients, understanding this distinction provides a stronger foundation for evaluating THC percentages, CBD products, minor cannabinoids, terpene profiles, dosing, and emerging cannabinoid research.